WHO and St. Jude to dramatically increase global access to childhood cancer medicines
The World Health Organization and St. Jude Children’s Research Hospital today announced plans to establish a platform that will dramatically increase access to childhood cancer medicines around the world according to a joint statement.
The Global Platform for Access to Childhood Cancer Medicines, the first of its kind, will provide an uninterrupted supply of quality-assured childhood cancer medicines to low-and middle-income countries. St. Jude is making a six-year, US$ 200 million investment to launch the platform, which will provide medicines at no cost to countries participating in the pilot phase. This is the largest financial commitment for a global effort in childhood cancer medicines to date.
Each year, an estimated 400,000 children worldwide develop cancer. The majority of children living in low-and middle-income countries are unable to consistently obtain or afford cancer medicines. As a result, nearly 100 000 children die each year.
The new platform aims to provide safe and effective cancer medicines to approximately 120 000 children between 2022 and 2027, with the expectation to scale up in future years. This platform will provide end-to-end support ̶consolidating global demand to shape the market; assisting countries with the selection of medicines; developing treatment standards; and building information systems to track that effective care is being provided and to drive innovation.
This approach will open a new chapter in access to cancer care by addressing medicine availability in low-and middle-income countries that is often complicated by higher prices, interruptions in supply and out-of-pocket expenditures that result in financial hardship.
According to a WHO Noncommunicable Disease Country Capacity survey published in 2020, only 29% of low-income countries report that cancer medicines are generally available to their populations compared to 96% of high-income countries. By consolidating the needs of children with cancer globally, the new platform will curtail the purchasing of sub-standard and falsified medicines that results from unauthorized purchases and the limited capacity of national regulatory authorities.
“Unless we address the shortage and poor quality of cancer medicines in many parts of the world, there are very few options to cure these children,” said Carlos Rodriguez-Galindo, M.D., executive vice president and chair of the St. Jude Department of Global Pediatric Medicine and director of St. Jude Global. “Healthcare providers must have access to a reliable source of cancer medicines that constitute the current standard of care. We at St. Jude, with our co-founding partners at WHO and many vital partners around the world, can help achieve that.”
